Where Venture Meets Philanthropy


Induran Venture Accomplishments

Induran accelerates ground breaking technologies that solve problems confronting humans. Induran has experience starting, growing, and running companies across the spectrum of biotechnology, including the world`s first continuous process bio fuel refinery, eco-friendly agriculture, anti viral therapeutics, drug delivery technology, novel therapeutics, and molecular diagnostics. 


Venture Philanthropy is Social Impact Investing

After productive careers in pharmaceuticals and venture capital the Induran Partners are focused on social impact investing, through venture philanthropy. 

We have run philanthropic campaigns. And we have decades of experience investing in early stage companies developing life saving products.

We have worked with Family Offices, Qualified Investors, Angel Networks, and Multinational Corporations.


Invest in NeuroQore for Social Impact

NeuroQore will soon commence clinical studies in an attempt to validate a novel therapy for adolescents suffering from Treatment Resistant Depression who are at eminent risk of suicide. It does so with a breakthrough electromagnetic pulse sent directly to the brain. NeuroQore calls this technology First Dawn.  

For 10 years NeuroQore has worked with a team of electrical engineers to create a shaped and precisely controlled pulse for neuromodulation.  The technology is now locked down and ready for submission to the FDA as a new investigational  device. 

We are hopeful that this device will also prove useful as a treatment for Autism.

Current Projects


NeuroQore Inc.

First Dawn is a breakthrough therapy for adolescents with treatment resistant depression at risk for suicide.  We anticipate that the therapy will be effective in treating children with Autism.

NeuroQore is about to conduct a pivotal study to validate it's First Dawn  technology. Further studies are anticipated for first responders, the military, and others suffering from major depressive disorder and at risk of suicide.  The technology will also be tested for effectiveness in treating strokes and a  broad range of other neurological disorders. For more information visit www.neuroqore.com 


SignPost Cancer Dx Inc.

Induran Ventures founded SignPost Cancer Dx Inc. to create BreastDefense and help advance the worlds shift to precision medicine. 

SignPost is at the very forefront- globally- in the development of molecular diagnostics. If you would like to know more about SignPost visit: www.breastdefense.org  


GraySpace Therapeutics Inc.

GraySpace Therapeutics Inc. is in the first wave of a new class of pharmaceutical companies that treat specific ailments by slowing the fundamental processes of aging.

Our initial target is people suffering from neurodegenerative diseases like Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Ultimately our market will include approximately 2 billion adults over 40 years of age facing cognitive decline and neurodegenerative diseases. 

Past Projects


Performance Plants


A global leader in agricultural and biofuel biotechnology. A plant-trait company with field-tested proven technologies to help farmers, industry and biofuel users meet the challenges of feeding and fueling the world of tomorrow...today.


Defryus Inc.

Defyrus, developed an anti viral therapy ZMapp to treat Ebola.  ZMapp was the first antibody therapy proven effective in treating humans, post exposure, for this highly infectious disease. 



 The world's first continuous process bio diesel refinery. Biox began as a test plant and now has two manufacturing locations in Canada and a joint venture with the US company World Energy of Houston.

Bio Diesel is a clean high performing alternative to petroleum diesel and is a low cost solution to help combat climate change.

Our Team


Peter Blaney

Barry Markowsky

Peter Blaney

For 30 years Peter has been active in biotechnology start ups that have led to products in bio fuels, agricultural biotech, anti viral therapeutics, drug delivery and molecular diagnostics.


Paul Lucas

Barry Markowsky

Peter Blaney

Paul is Past President and CEO of GlaxoSmithKline Canada. Paul has enormous experience in bringing new technology to the marketplace.


Barry Markowsky

Barry Markowsky

Barry Markowsky

Barry is Past Vice President Development and Director at GlaxoSmithKline Canada. Barry has the unique combination of a science background and experience in negotiating and closing development deals.


Sign up to hear from us.

Contact Us

Send Message

Induran Ventures Inc.

P.O Box 26, Kingston, Ontario, Canada K7L 4V6